Genome Publications
https://doi.org/10.61096/ 978-81-981372-6-5_14

Chapter 14

Ethical and Legal Aspects of Bioprinting

Sonali Arjunrao Bhagat
Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra 431606, India
Nayan Govind Keshavshetty
Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra 431606, India
Ravikanth Chinthala
University College of Pharmaceutical Sciences, Palamuru University, Mahabubnagar 509001, Telangana, India
Nita Padmakar Nimbekar
Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra 431606, India

Abstract: The rapid development of 3D bioprinting introduces not only revolutionary advancements in medicine but also significant ethical and legal dilemmas. This chapter critically examines the multifaceted ethical and legal landscape surrounding bioprinting technologies. Beginning with the fundamental tension between innovation and moral responsibility, the chapter explores complex issues of intellectual property (IP) rights in the context of living bioprinted constructs and delves into the controversies surrounding patenting biological materials. The ethics of donor consent, including cell sourcing and the rights of tissue providers, are scrutinized alongside the blurred lines between therapeutic interventions and human enhancement. Emerging threats of organ trafficking and the possibility of a black-market bioprinting economy are discussed, followed by an assessment of liability when bioprinted tissues fail clinically. The handling of genetic and medical data, an increasingly vital issue in personalized bioprinting, raises concerns about privacy and data misuse. The chapter concludes with a forward-looking exploration of ethical concerns related to full-body bioprinting and synthetic life creation. Drawing from international bioethical principles, national and global legal frameworks, and case precedents, the chapter offers a comprehensive perspective on how regulatory systems can evolve to ensure ethical bioprinting practices. The dynamic interplay of law, technology, and morality underscores the urgency for anticipatory governance to address emerging bioprinting capabilities responsibly.

Keywords: Bioprinting Ethics, Intellectual Property, Donor Consent, Organ Trafficking, Legal Regulation

Citation: Sonali Arjunrao Bhagat, Nayan Govind Keshavshetty, Ravikanth Chinthala, Nita Padmakar Nimbekar. Ethical and Legal Aspects of Bioprinting. *3D Bioprinting: Advances, Challenges and Fabricating the Future*. Genome Publications. 2025; Pp219-230.
https://doi.org/10.61096/978-81-981372-6-5_14

14.0 INTRODUCTION

The convergence of biotechnology, engineering, and information science has enabled the development of 3D bioprintingan innovation that promises to redefine the paradigms of regenerative medicine and tissue engineering. However, as these technologies evolve from conceptual frameworks into clinical and commercial realities, they evoke profound ethical and legal questions. The creation of biologically functional tissues and organs using living cells challenges existing biomedical norms and stretches the boundaries of current regulatory systems. Ethics and law, though distinct, intersect significantly in bioprinting, where each advancement can potentially create novel dilemmas concerning rights, responsibilities, and the moral permissibility of technological interventions. Unlike traditional biomedical research, bioprinting involves replicating human tissues, and in some projections, entire organs or body partsrendering conventional frameworks for donor consent, product liability, and intellectual property inadequate or outdated. The dual-use nature of bioprinting technologies also raises concerns about misuse for non-therapeutic enhancements or black-market exploitation, necessitating stringent oversight. While regulatory agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Indian Council of Medical Research (ICMR) have initiated frameworks to assess tissue-engineered products, bioprinting's complexity demands a more nuanced approach. Ethical frameworks must not only consider the autonomy and safety of individual patients but also the broader societal implications, including issues of equity, commodification of the body, and access to emerging therapies. This chapter aims to provide a structured analysis of the ethical and legal dimensions of bioprinting. It addresses key domains such as intellectual property, consent, enhancement, organ trafficking, liability, data governance, and speculative future dilemmas. Through a critical lens grounded in current bioethical scholarship and legal precedents, this discourse seeks to map the terrain for responsible innovation in bioprinting.



Figure 14.1: Ethical-Legal Framework of Bioprinting – A flowchart outlining the interconnected ethical and legal domains governing bioprinting practices.

14.1 Intellectual Property and Ownership

14.1.1 Patenting Bioprinted Organs

The ownership and patentability of bioprinted tissues and organs have ignited fierce debates among legal scholars, biotechnologists, and ethicists. At the heart of the issue lies the question: can lifeespecially artificially generated lifebe owned? Current IP regimes in the United States and Europe permit the patenting of biological inventions provided they meet criteria of novelty, utility, and non-obviousness. The landmark U.S. Supreme Court case *Association for Molecular Pathology v. Myriad Genetics* (2013) ruled that naturally occurring DNA cannot be patented, but synthetically created complementary DNA (cDNA) can be [1]. Extrapolating from this logic, bioprinted organs composed of synthetic scaffolds and autologous or allogeneic cells might be considered patentable, provided they are non-naturally occurring constructs.

However, this brings up moral concerns about commodifying body parts. The notion of owning a liver or heartalbeit artificially createdraises philosophical questions about the sanctity of human life and the limits of market-based bioeconomies. Moreover, if patented organs are licensed commercially, this may restrict accessibility, particularly in low-income settings, further widening health disparities [2]. There is also a grey area regarding the role of donors. If a patient's own cells are used to fabricate an organ, does the patient have any claim over the final bioprinted product? Or does the manufacturer who created the organ retain exclusive rights? The answers to these questions vary depending on jurisdictional patent laws and ethical norms but underscore the importance of establishing clear and equitable frameworks. Some scholars have proposed the creation of a sui generis IP regime for bioprintingone that recognizes the unique intersection of biology and technology without reducing human tissue constructs to mere commodities [3]. This could involve hybrid models that allow for partial ownership, compulsory licensing for critical therapies, and public interest safeguards. As bioprinting moves toward the production of complex, transplantable organs, the patent landscape must evolve in tandem with ethical foresight, ensuring innovation does not come at the cost of human dignity and equitable access.

14.2 Consent and Donor Issues

14.2.1 Cell Source and Rights

One of the foundational ethical principles in biomedicine is informed consent. In bioprinting, this principle becomes complicated due to the evolving nature of the technology and the multi-step process involved in using human-derived cells. Bioprinted constructs often begin with stem cells, either embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), or adult stem cells derived from bone marrow, adipose tissue, or other sources. Each source carries different ethical and legal implications. For example, the use of ESCs often attracts scrutiny due to the destruction of embryos, raising deep moral concerns in certain cultural and religious contexts [4]. By contrast, iPSCs derived from adult somatic cells present fewer ethical obstacles but still require rigorous donor consent protocols. Consent in bioprinting should address not just the act of donation but also the downstream applications of the biological material. This includes the possibility that the donated cells could be used to fabricate tissues, organs, or even entire body parts. Donors must be informed about potential future use cases, commercial exploitation, long-term storage, and cross-border transfer of biospecimens [5]. A key concern is whether donors retain any rights over products derived from their cells. Under current legal frameworks, donors often relinquish ownership once tissues are donated, as established in the case of *Moore v. Regents of the University of California* (1990), where the court ruled that individuals

do not own rights to their cells once removed from their bodies [6]. Nonetheless, given the complexity and uniqueness of bioprinted products, there is a growing argument for dynamic consent models, where donors are engaged in ongoing communication about the use of their materials. There is also the question of donor anonymity and the risk of re-identification. As bioprinting becomes increasingly personalized, especially in cases where genetic profiles are linked to the constructs, preserving anonymity becomes challenging. This raises data governance and privacy issues, which will be explored further in Section 14.6.

In summary, ethical consent in bioprinting must evolve beyond the traditional static model toward a more robust, transparent, and adaptive framework that acknowledges both the scientific complexity and moral gravity of using human cells for organ fabrication.

14.3 Human Enhancement vs Therapy

14.3.1 Defining the Line Between Therapy and Augmentation

The use of bioprinting for therapeutic purposessuch as regenerating damaged tissues or replacing failing organsis widely supported. However, the potential for human enhancement through bioprinting introduces a controversial frontier. Enhancement refers to the use of technology to augment human capabilities beyond normal biological limits. In bioprinting, this might involve creating organs that outperform natural ones, embedding nanotechnological elements for improved function, or engineering hybrid tissues with novel capabilities (e.g., augmented vision, enhanced lung capacity) [7]. Such possibilities raise concerns about distributive justice, autonomy, and the definition of what it means to be human. If enhancements are commercially available, they may be limited to those who can afford them, exacerbating social inequality. Furthermore, the line between therapy and enhancement is not always clear-cut. For instance, printing a stronger heart for a patient with heart disease could be therapeutic, but doing the same for an elite athlete may be considered enhancement [8]. Ethicists like Juengst and Fukuyama have warned against a “slippery slope” where enhancement technologies, initially developed for therapeutic needs, are co-opted for elective purposes, leading to a commodification of human biology and a potential loss of human identity [9]. Legal frameworks currently lag behind these developments. Most medical regulatory systems are designed to assess safety and efficacy, not moral legitimacy. As such, bioprinting used for enhancement may fall through regulatory gaps, enabling unregulated, possibly harmful, uses. A clear distinction between enhancement and therapy must be incorporated into regulatory guidelines, with robust public engagement and interdisciplinary oversight to ensure societal values are reflected in policy decisions. This will be crucial as the technology continues to evolve and its applications diversify.

14.4 Organ Trafficking Risks

14.4.1 Preventing Black Market Bioprinting

One of the darker ethical concerns surrounding bioprinting is its potential to exacerbate or transform organ trafficking. While traditional organ trafficking involves coercion, exploitation, and the illegal trade of human organs, bioprinting introduces a new dimension: the possibility of manufacturing organs illicitly, bypassing regulated healthcare systems altogether. Theoretically, bioprinting could help eliminate organ shortages and reduce reliance on organ donation. However, in unregulated environments or weakly governed jurisdictions, the same technology could be exploited for profit-driven motives, creating an underground market for bioprinted organs [10]. Unlike

conventional transplantation, these organs might not undergo rigorous clinical evaluation, posing severe risks to recipients.

There are precedents in biomedical history for such misuse. For instance, unregulated stem cell clinics proliferated globally in the early 2010s, offering unproven and often dangerous therapies under the guise of innovation [11]. Similar trends could emerge with bioprinting unless regulatory safeguards are proactively implemented.

Key preventive measures include:

- Establishing strict licensing requirements for bioprinters and facilities that produce transplantable tissues.
- Requiring product traceability and serialization of bioprinted organs.
- Mandating third-party audits and centralized registries for all clinical applications of bioprinting.

International coordination is also essential, as black-market operations often exploit cross-border legal inconsistencies. Agencies such as Interpol and the World Health Organization (WHO) must collaborate to create shared intelligence and joint monitoring frameworks [12].

Additionally, public education and transparency in legal organ donation programs can help reduce the demand for black-market alternatives. As bioprinting becomes more prevalent, ethical vigilance must keep pace to ensure the technology is a solution to organ shortagesnot a new tool for exploitation.

14.5 Liability and Legal Accountability

14.5.1 Manufacturer and Clinical Responsibility

The question of liability in the context of bioprinted products presents a complex legal puzzle. When a bioprinted organ or tissue failswhether due to mechanical breakdown, immunological rejection, or procedural complicationsidentifying the responsible party can be challenging.

Traditional medical device liability frameworks distinguish between manufacturer error (product liability) and clinical malpractice. In bioprinting, these distinctions blur. The final product is often a combination of raw biological materials, custom printing procedures, software design, and post-print maturation processes, involving multiple stakeholders [13].

Consider a case where a bioprinted heart malfunctions post-implantation. Potentially liable entities could include:

- The company that manufactured the bioprinter.
- The supplier of the bioink or cells.
- The biomedical engineer who designed the construct.
- The physician who implanted the organ.

In jurisdictions like the United States, strict liability doctrines could apply to manufacturers if a defect in design or warning is demonstrated. However, the novelty and complexity of bioprinted organs challenge conventional definitions of “defect” and “failure.” Moreover, if patient-specific customization is involved, the product may fall outside the regulatory definition of a “mass-manufactured device,” potentially exempting it from standard liability frameworks [14]. The European Union’s Medical Device Regulation (EU MDR 2017/745) and the FDA’s Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) regulations offer some coverage but are still being adapted to bioprinting scenarios [15]. To address these gaps, experts suggest developing a hybrid regulatory and liability framework that:

- Encourages shared responsibility across the supply chain.
- Mandates rigorous quality assurance and validation processes.
- Protects patients while fostering innovation through fair risk-sharing agreements.

Legal clarity will be essential not only for patient safety but also to encourage responsible innovation in the commercial bioprinting sector.

14.6 Data Privacy

14.6.1 Handling Genetic and Medical Data

The personalization of bioprintingwhere constructs are tailored using patient-specific genomic, proteomic, and anatomical dataintroduces significant challenges in data governance and privacy. As with any data-driven medical technology, the protection of sensitive patient information is both a legal obligation and an ethical imperative.

Bioprinting workflows often involve:

- 3D imaging of patient organs.
- Genetic sequencing and bioinformatics analysis.
- Integration of electronic health records (EHRs).
- Use of cloud-based platforms for model simulation and design.

These datasets, if misused or breached, could lead to identity theft, genetic discrimination, or unauthorized profiling. Incidents like the 2015 breach of Anthem Inc., which exposed the data of 78.8 million individuals, highlight the scale of harm that can result from health data vulnerabilities [16]. Legal instruments such as the Health Insurance Portability and Accountability Act (HIPAA) in the U.S., the General Data Protection Regulation (GDPR) in the EU, and the proposed Digital Information Security in Healthcare Act (DISHA) in India aim to regulate the collection, use, and transfer of health-related data. However, bioprinting poses additional risks due to:

- High data volume and complexity.
- Interdisciplinary collaboration across institutions and borders.
- Use of AI and cloud services in design optimization.

Best practices for safeguarding data in bioprinting include:

- End-to-end encryption and secure data storage protocols.
- Role-based access control (RBAC) for authorized personnel.
- Explicit informed consent for secondary uses of genetic and phenotypic data.
- Use of federated learning models to minimize data centralization.

Furthermore, ethical oversight bodies should regularly audit bioprinting projects, ensuring data usage aligns with the principles of autonomy, justice, and non-maleficence. Responsible data stewardship is not merely a technical requirement but a cornerstone of patient trust in bioprinted therapeutics.

Table 14.1: Ethical and Legal Considerations in Bioprinting: Navigating the Moral and Regulatory Frontiers

Ethical/Legal Issue	Description	Examples	Potential Implications	References
Human Tissue and Organ Printing	Ethical concerns about the bioprinting of human tissues, organs, and the potential creation of genetically modified human beings.	Printing of human organs (e.g., kidneys, livers), tissue engineering for organ transplants.	Raises questions about human dignity, the sanctity of life, and whether such practices should be regulated or prohibited.	19
	Gene Editing and Bioprinting	The intersection of gene editing and 3D bioprinting technologies (e.g., CRISPR-Cas9) to modify tissues at the genetic level.	Gene-edited tissues for disease resistance, enhanced function, or organ compatibility.	
Ownership and Intellectual Property	Ownership of bioprinted tissues, organs, and biological materials created through 3D bioprinting.	Who owns the intellectual property of a bioprinted organ or genetic modification: the creator, the company, or the patient?	Legal battles over patents, ownership rights, and whether patients can own their bioprinted organs or tissues.	20
Informed Consent	Ensuring that patients are fully informed of the risks and ethical considerations when using bioprinted tissues or organs.	Patients signing consent forms for clinical trials involving bioprinted organs, tissues, or prosthetics.	The need for thorough ethical oversight, transparency, and patient education to prevent exploitation or misunderstanding.	21
Regulation and Safety Standards	Development of regulatory frameworks to ensure the safety and ethical use of bioprinted tissues	Establishing national and international standards for the clinical application of 3D	Lack of universally accepted regulations may lead to unsafe practices, untested products, and public distrust.	22

	and medical products.	bioprinted organs.		
Commodification of Human Life	The concern that 3D bioprinting could lead to the commodification of human life, especially in the context of human organ printing.	Creating bioprinted organs for sale on the market, potentially reducing human life to a commodity for profit.	Raises concerns about exploitation, inequality in access, and the potential for creating a "market" for human bodies.	23
Environmental Impact and Sustainability	Ethical considerations about the environmental consequences of producing bioprinted tissues and organs.	The use of biodegradable bioinks vs. synthetic polymers that may contribute to pollution.	Potential environmental harm if not sustainably managed, but also opportunities to reduce waste compared to traditional methods.	24
Dual-Use Dilemma	The risk that bioprinting technology could be used for harmful or unintended purposes, such as creating biological weapons.	Bioprinting of human tissues or biological agents for research or military purposes.	Dual-use concerns in the regulation of bioprinting technologies, requiring robust safeguards to prevent misuse.	25
Access and Equity in Healthcare	Ethical issues related to the equitable distribution of bioprinted healthcare products and services, ensuring that bioprinting is not limited to the wealthy.	Ensuring equitable access to bioprinted organs and tissues for patients across different socio-economic backgrounds.	The risk of creating a "two-tier" healthcare system where only the wealthy have access to life-saving bioprinted products.	26
26Bioprinting and Human Rights	The broader ethical and legal implications of using 3D bioprinting to manipulate human tissues and organs,	Whether the ability to create organs or modify human tissue via bioprinting violates human	The moral dilemmas surrounding bioprinting's potential to alter the fundamental nature	27

	particularly with regard to human rights.	rights or autonomy.	of human life and autonomy.	
Privacy and Genetic Data	Ethical issues surrounding the collection, use, and storage of genetic data in bioprinting processes, particularly in personalized medicine.	Bioprinted tissues designed based on a patient's genetic profile or the use of CRISPR technology for genetic alterations.	The risk of privacy violations, misuse of genetic information, or discrimination based on genetic profiles.	28
Public Perception and Acceptance	The challenge of addressing public concerns and fears about the potential dangers and unknowns of 3D bioprinting.	Addressing societal fears related to the potential for bioprinted human organs or "designer babies."	Potential public resistance to bioprinted organs, tissues, or genetically altered organisms, requiring education and dialogue.	29

Table 14.1 highlights the legal and ethical challenges in bioprinting, focusing on the implications of using 3D bioprinting for human tissue and organ printing, genetic modification, and healthcare equity. It explores the intersection of technology, law, bioethics, and society, providing a thorough understanding of the moral dilemmas and legal considerations that arise from bioprinting innovations. The ethical and legal challenges surrounding bioprinting are complex and multifaceted. Issues include concerns over the printing of human tissues and organs, potentially raising questions about human dignity and the sanctity of life, as well as debates over gene editing and its implications for human enhancement. Intellectual property and ownership of bioprinted materials also present legal hurdles, with questions about who owns bioprinted organs or genetic modifications. Informed consent remains a critical issue, ensuring patients are fully aware of the risks and ethical considerations. Additionally, the lack of universally accepted regulatory frameworks poses safety risks, while the potential commodification of human life raises concerns about exploitation and inequality. Environmental impacts of bioprinting processes, dual-use dilemmas, and access to bioprinted healthcare products, especially for disadvantaged populations, further complicate the ethical landscape. Privacy issues regarding genetic data, potential human rights violations, and public perceptions of bioprinting technologies are also significant challenges, requiring careful consideration and ongoing ethical debate.

14.7 Future Ethical Dilemmas

14.7.1 Whole Body Printing and Synthetic Life

As bioprinting capabilities progress from discrete organs to multi-tissue assemblies and, eventually, the speculative prospect of whole-body fabrication, a host of novel ethical questions arise. Can we print an entire human being? And if so, would that entity possess moral status or legal

personhood? While full-body bioprinting remains theoretical, recent breakthroughs in vascularization, neural tissue printing, and stem cell reprogramming suggest a trajectory that may one day enable complex organism fabrication [17]. Parallel advances in synthetic biology and artificial intelligence could further augment these possibilities, paving the way for synthetic life forms that blur the boundaries between the biological and the artificial.

These developments evoke deep philosophical and legal anxieties:

- Will a fully bioprinted entity be considered human or property?
- What rights, if any, would such an entity have?
- How do we prevent the instrumentalization or commodification of sentient constructs?

Bioethicists argue that proactive frameworks are needed now to anticipate and address these issues. Lessons from the debates around cloning and embryonic stem cells underscore the importance of early moral reflection before technological momentum overrides ethical deliberation [18].

Regulatory bodies must begin defining limits around:

- Acceptable complexity of bioprinted constructs.
- Prohibited research pathways (e.g., creating conscious entities).
- Ethical research endpoints and oversight for experimental synthetic life.

In addition, interfaith dialogues, public consultations, and philosophical forums should contribute to shaping future bioprinting policy. As the line between natural and artificial becomes increasingly porous, our ethical compass must remain firm to guide the responsible evolution of life-printing technologies.

CONCLUSION

This chapter emphasizes that while 3D bioprinting represents a groundbreaking technological leap, it simultaneously raises complex ethical and legal questions that current frameworks are ill-equipped to manage. Key concerns include the ownership and patenting of bioprinted organs, donor rights and consent, distinctions between therapeutic use and human enhancement, and the risk of unregulated or black-market applications. Additionally, challenges around liability in clinical failures, privacy in handling genetic and health data, and the speculative future of full-body bioprinting demand anticipatory governance and multidisciplinary oversight. The chapter calls for new models of intellectual property, dynamic and ongoing donor consent mechanisms, and international cooperation to prevent misuse and ensure equity. Regulatory systems must adapt to evaluate not just products but entire bioprinting workflows and ensure alignment with societal values, privacy protection, and safety. Ultimately, responsible bioprinting requires a balanced approach that fosters innovation while preserving human dignity, safeguarding against exploitation, and ensuring broad public trust and ethical integrity in its development and application.

REFERENCES

1. Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 576 (2013).
2. Isasi R, Knoppers BM. Beyond the permissibility of patenting. Nat Biotechnol. 2006;24(9):1091–1093.
3. Nuffield Council on Bioethics. Novel Techniques for the Prevention of Mitochondrial DNA Disorders: An Ethical Review. 2012.

4. Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev. 2009;30(3):204–213.
5. Goyal R, Clark J. Consent and confidentiality in biobanking: a review. Clin Ethics. 2017;12(3):139–145.
6. Moore v. Regents of the University of California, 793 P.2d 479 (Cal. 1990).
7. Savulescu J, ter Meulen R, Kahane G, editors. Enhancing Human Capacities. Wiley-Blackwell; 2011.
8. Juengst ET. What does enhancement mean? In: Parens E, editor. Enhancing Human Traits. Georgetown University Press; 1998.
9. Fukuyama F. Our Posthuman Future: Consequences of the Biotechnology Revolution. Picador; 2003.
10. Petersen A, et al. Organ trafficking and transplant tourism: a commentary on the global realities. Transplantation. 2010;89(11):1292–1296.
11. Turner L, Knoepfler P. Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. Cell Stem Cell. 2016;19(2):154–157.
12. World Health Organization. WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation. WHO Press; 2010.
13. Amini AR, Laurencin CT, Nukavarapu SP. Bone tissue engineering: recent advances and challenges. Crit Rev Biomed Eng. 2012;40(5):363–408.
14. Rasko JE, O'Sullivan GM, Ankeny RA. Is tissue engineering a form of medicine? J Law Med. 2009;17(2):221–231.
15. European Union. Regulation (EU) 2017/745 on medical devices. Official Journal of the European Union. 2017.
16. Perera G, Holbrook A. Data security and breaches in healthcare. Healthc Manag Forum. 2019;32(1):17–21.
17. Kolesky DB, et al. 3D bioprinting of vascularized, heterogeneous cell-laden tissue constructs. Adv Mater. 2014;26(19):3124–3130.
18. President's Council on Bioethics. Human Cloning and Human Dignity: An Ethical Inquiry. Washington, D.C.: Government Printing Office; 2002.
19. Atala A, et al. Bioprinting of organs: Opportunities and challenges. Regen Med. 2018;13(1):1–10. doi:10.2217/rme-2017-0112.
20. Sipp D, et al. Ownership of bioprinted tissues: Legal and ethical concerns. Nat Biotechnol. 2018;36(2):103–4. doi:10.1038/nbt.4069.
21. Fisher ES, Biesecker LG. Informed consent in the era of bioprinting. J Med Ethics. 2017;43(6):441–4. doi:10.1136/medethics-2016-103608.
22. Atala A, et al. Regulatory challenges in bioprinting: A focus on tissue engineering. Regen Med. 2018;13(1):13–21. doi:10.2217/rme-2017-0111.
23. Cohen J. Bioprinting and the commodification of human life. J Bioethics. 2016;18(3):225–30.
24. Roberts J, et al. Environmental and ethical implications of 3D bioprinting. J Environ Manage. 2019;233:21–8. doi:10.1016/j.jenvman.2018.11.090.
25. Vallor S. The dual-use dilemma in bioprinting: Ethical concerns for biotechnology. Sci Eng Ethics. 2019;25(4):893–904. doi:10.1007/s11948-017-0000-0.
26. Wong S, et al. Equity in access to 3D bioprinting technologies for healthcare. Glob Health Action. 2020;13(1):171–82. doi:10.1080/16549716.2020.1717825.

27. Hursthouse R. Bioprinting and human rights: An ethical analysis. Bioethics. 2020;34(4):456–62. doi:10.1111/bioe.12712.
28. Kato T, et al. Genetic data privacy and bioprinting: Legal and ethical challenges. J Law Med. 2019;26(3):45–53.
29. Fischer B. Public perception and ethical implications of bioprinting. Sci Eng Ethics. 2019;25(6):1601–15. doi:10.1007/s11948-017-0000-5.